Anti-CDKN2A antibody (N-Term) {FITC}

Clonality:	Polyclonal
Conjugation:	FITC
Isotype:	IgG
Purification:	Affinity Purified
Concentration:	1.00-1.25 mg/ml µg/µl
Dilution Range:	WB: 1:500 DB: 1:10, 000 ELISA: 1:10, 000 IP: 1:200 IHC: 1:100
Storage Instruction:	Store at-20°C for long term storage. Avoid freeze-thaw cycles.

Gene Symbol:	CDKN2A
Gene ID:	1029
Uniprot ID:	ARF_HUMAN
Immunogen Region:	N-Term
Immunogen:	N-epitope synthetic peptide corresponding to unique amino acid sequence on p14ARF protein

Post Translational Modifications	Ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardless of the absence of lysine residues. Ubiquitination leads to its proteasomal degradation. In cancer cells, however, TRIP12 is located in a different cell compartment, preventing ubiquitination and degradation.
Function	Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Plays a role in inhibiting ribosome biogenesis, perhaps by binding to the nucleolar localization sequence of transcription termination factor TTF1, and thereby preventing nucleolar localization of TTF1. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. Isoform smARF: May be involved in regulation of autophagy and caspase-independent cell death.the short-lived mitochondrial isoform is stabilized by C1QBP.
Protein Name	Tumor Suppressor Arf Alternative Reading Frame Arf Cyclin-Dependent Kinase Inhibitor 2a P14arf
Database Links	Reactome: R-HSA-111471 Reactome: R-HSA-2559580 Reactome: R-HSA-2559585 Reactome: R-HSA-3108214 Reactome: R-HSA-3232118 Reactome: R-HSA-6804757 Reactome: R-HSA-69541 Reactome: R-HSA-8941858 Reactome: R-HSA-9645722 Reactome: R-HSA-9646303 Reactome: R-HSA-9646304 Reactome: R-HSA-9759194 Reactome: R-HSA-2559582 Reactome: R-HSA-69231 Reactome: R-HSA-8853884 Reactome: R-HSA-9630791 Reactome: R-HSA-9630794 Reactome: R-HSA-9632697 Reactome: R-HSA-9632700
Cellular Localisation	Nucleus Nucleolus Nucleoplasm Isoform Smarf: Mitochondrion
Alternative Antibody Names	Anti-Tumor Suppressor Arf antibody Anti-Alternative Reading Frame antibody Anti-Arf antibody Anti-Cyclin-Dependent Kinase Inhibitor 2a antibody Anti-P14arf antibody Anti-CDKN2A antibody Anti-CDKN2 antibody Anti-MLM antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance